Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics

Arrowhead Pharmaceuticals, Inc. (ARWR): $23.58

1.52 (-6.06%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add ARWR to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#321 of 349

in industry

ARWR Price/Volume Stats

Current price $23.58 52-week high $39.83
Prev. close $25.10 52-week low $20.67
Day low $23.51 Volume 838,900
Day high $25.20 Avg. volume 1,327,250
50-day MA $24.17 Dividend yield N/A
200-day MA $27.77 Market Cap 2.93B

ARWR Stock Price Chart Interactive Chart >


Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio


Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.


ARWR Latest News Stream


Event/Time News Detail
Loading, please wait...

ARWR Latest Social Stream


Loading social stream, please wait...

View Full ARWR Social Stream

Latest ARWR News From Around the Web

Below are the latest news stories about ARROWHEAD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ARWR as an investment opportunity.

Arrowhead Pharmaceuticals Inc CEO Christopher Anzalone Sells 12,000 Shares

Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) CEO Christopher Anzalone sold 12,000 shares of the company's stock on December 20, 2023, according to a recent SEC filing.

Yahoo | December 24, 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease

PASADENA, Calif., December 21, 2023--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement mediated renal disease, such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-st

Yahoo | December 21, 2023

Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PASADENA, Calif., December 20, 2023--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 8:15 a.m. PT.

Yahoo | December 20, 2023

ARWR: Updates on Plozasiran and Zodasiran at AHA 2023…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Updated Clinical Data for Cardiometabolic Candidates Presented at AHA 2023 On November 13, 2023, Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced new clinical data for the Phase 2 SHASTA-2 and MUIR studies of plozasiran (ARO-APOC3) and the ARCHES-2 study of zodasiran (ARO-ANG3) were presented at the American

Yahoo | December 5, 2023

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q4 2023 Earnings Call Transcript November 29, 2023 Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only. After the presentation, there will be an opportunity to ask questions. I will now hand the conference call over to Vince […]

Yahoo | December 1, 2023

Read More 'ARWR' Stories Here

ARWR Price Returns

1-mo -5.00%
3-mo -16.47%
6-mo -22.31%
1-year -34.08%
3-year -72.47%
5-year -16.15%
YTD -22.94%
2023 -24.56%
2022 -38.82%
2021 -13.59%
2020 20.97%
2019 410.71%

Continue Researching ARWR

Here are a few links from around the web to help you further your research on Arrowhead Pharmaceuticals Inc's stock as an investment opportunity:

Arrowhead Pharmaceuticals Inc (ARWR) Stock Price | Nasdaq
Arrowhead Pharmaceuticals Inc (ARWR) Stock Quote, History and News - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!